The Crystal Structure of Cobra Venom Factor, a Cofactor for C3- and C5-Convertase CVFBb

Structure

Volumn 17, Issue 4, 2009, Pages 611-619

  Krishnan, Vengadesan ^a   Ponnuraj, Karthe ^b   Xu, Yuanyuan ^c   Macon, Kevin ^a   Volanakis, John E ^d   Narayana, Sthanam V L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MADRAS   (India)

^c The University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

PROTEINS

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COBROTOXIN;

ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANIMALS; BINDING SITES; COBRA VENOMS; COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; CRYSTALLOGRAPHY, X-RAY; MODELS, CHEMICAL; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

MAMMALIA; NAJA NAJA;

EID: 64049115651     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2009.01.015     Document Type: Article

References (63)

1. Alper C.A., and Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science 191 (1976) 1275-1276
2. Baxter R.H., Chang C.I., Chelliah Y., Blandin S., Levashina E.A., and Deisenhofer J. Structural basis for conserved complement factor-like function in the antimalarial protein TEP1. Proc. Natl. Acad. Sci. USA 104 (2007) 11615-11620
3. Becherer J.D., Alsenz J., Esparza I., Hack C.E., and Lambris J.D. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry 31 (1992) 1787-1794
4. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
5. Clemenza L., and Isenman D.E. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21). J. Immunol. 165 (2000) 3839-3848
6. Daha M.R., Fearon D.T., and Austen K.F. C3 requirements for formation of alternative pathway C5 convertase. J. Immunol. 117 (1976) 630-634
7. DiScipio R.G., Smith C.A., Müller-Eberhard H.J., and Hugli T.E. The activation of human complement component C5 by a fluid phase C5 convertase. J. Biol. Chem. 258 (1983) 10629-10636
8. Dyson H.J., and Wright P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6 (2005) 197-208
9. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
10. Emsley J., Knight C.G., Farndale R.W., Barnes M.J., and Liddington R.C. Structural basis of collagen recognition by integrin α2β1. Cell 101 (2000) 47-56
11. Fishelson Z. Complement C3: a molecular mosaic of binding sites. Mol. Immunol. 28 (1991) 545-552
12. Fredslund F., Jenner L., Husted L.B., Nyborg J., Andersen G.R., and Sottrup-Jensen L. The structure of bovine complement component 3 reveals the basis for thioester function. J. Mol. Biol. 361 (2006) 115-127
13. Fredslund F., Laursen N.S., Roversi P., Jenner L., Oliveira C.L., Pedersen J.S., Nunn M.A., Lea S.M., Discipio R., Sottrup-Jensen L., and Andersen G.R. Structure of and influence of a tick complement inhibitor on human complement component 5. Nat. Immunol. 9 (2008) 753-760
14. Fritzinger D.C., Bredehorst R., and Vogel C.W. Molecular cloning and derived primary structure of cobra venom factor. Proc. Natl. Acad. Sci. USA 91 (1994) 12775-12779
15. Gowda D.C., Schultz M., Bredehorst R., and Vogel C.W. Structure of the major oligosaccharide of cobra venom factor. Mol. Immunol. 29 (1992) 335-342
16. Gowda D.C., Petrella E.C., Raj T.T., Bredehorst R., and Vogel C.W. Immunoreactivity and function of oligosaccharides in cobra venom factor. J. Immunol. 152 (1994) 2977-2986
17. x structures. Glycobiology 11 (2001) 195-208
18. Grier A.H., Schultz M., and Vogel C.W. Cobra venom factor and human C3 share carbohydrate antigenic determinants. J. Immunol. 139 (1987) 1245-1252
19. Hinshelwood J., Spencer D.I., Edwards Y.J., and Perkins S.J. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B. J. Mol. Biol. 294 (1999) 587-599
20. Horiuchi T., Macon K.J., Engler J.A., and Volanakis J.E. Site-directed mutagenesis of the region around Cys-241 of complement component C2. Evidence for a C4b binding site. J. Immunol. 147 (1991) 584-589
21. Hourcade D.E., Wagner L.M., and Oglesby T.J. Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis. J. Biol. Chem. 270 (1995) 19716-19722
22. Hourcade D.E., Mitchell L.M., and Oglesby T.J. Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding. J. Immunol. 162 (1999) 2906-2911
23. Hughes T.R., Piddlesden S.J., Williams J.D., Harrison R.A., and Morgan B.P. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem. J. 284 (1992) 169-176
24. Inal J.M., and Schifferli J.A. Complement C2 receptor inhibitor trispanning and the β-chain of C4 share a binding site for complement C2. J. Immunol. 168 (2002) 5213-5221
25. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., and Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437 (2005) 505-511
26. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., and Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 444 (2006) 213-216
27. 2-macroglobulin. Structure 6 (1998) 595-604
28. Jokiranta T.S., Hellwage J., Koistinen V., Zipfel P.F., and Meri S. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J. Biol. Chem. 275 (2000) 27657-27662
29. Koistinen V., Wessberg S., and Leikola J. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d. Complement Inflamm. 6 (1989) 270-280
30. Kolln J., Bredehorst R., and Spillner E. Engineering of human complement component C3 for catalytic inhibition of complement. Immunol. Lett. 98 (2005) 49-56
31. Lachmann P.J., and Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin. Exp. Immunol. 21 (1975) 109-114
32. Laich A., and Sim R.B. Complement C4bC2 complex formation: an investigation by surface plasmon resonance. Biochim. Biophys. Acta 1544 (2001) 96-112
33. Lambris J.D., and Müller-Eberhard H.J. Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity. J. Biol. Chem. 259 (1984) 12685-12690
34. Lambris J.D., Avila D., Becherer J.D., and Müller-Eberhard H.J. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides. J. Biol. Chem. 263 (1988) 12147-12150
35. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61 (2005) 458-464
36. Medicus R.G., Gotze O., and Müller-Eberhard H.J. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J. Exp. Med. 144 (1976) 1076-1093
37. Morgan B.P., and Harris C.L. Complement therapeutics; history and current progress. Mol. Immunol. 40 (2003) 159-170
38. Morganroth M.L., Till G.O., Kunkel R.G., and Ward P.A. Complement and neutrophil-mediated injury of perfused rat lungs. Lab. Invest. 54 (1986) 507-514
39. Morganroth M.L., Schoeneich S.O., Till G.O., Pickett W., and Ward P.A. Lung injury caused by cobra venom factor is reduced in rats raised on an essential fatty acid-deficient diet. Am. J. Physiol. 257 (1989) H1192-H1199
40. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
41. O'Keefe M.C., Caporale L.H., and Vogel C.W. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor. J. Biol. Chem. 263 (1988) 12690-12697
42. Oh K.S., Kweon M.H., Rhee K.H., Ho Lee K., and Sung H.C. Inhibition of complement activation by recombinant Sh-CRIT-ed1 analogues. Immunology 110 (2003) 73-79
43. Otwinowski Z., Borek D., Majewski W., and Minor W. Multiparametric scaling of diffraction intensities. Acta Crystallogr. A 59 (2003) 228-234
44. Pan Q., Ebanks R.O., and Isenman D.E. Two clusters of acidic amino acids near the NH2 terminus of complement component C4 α'-chain are important for C2 binding. J. Immunol. 165 (2000) 2518-2527
45. Pangburn M.K., and Müller-Eberhard H.J. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem. J. 235 (1986) 723-730
46. Pangburn M.K., Schreiber R.D., and Müller-Eberhard H.J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146 (1977) 257-270
47. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D Biol. Crystallogr. 57 (2001) 1373-1382
48. Sánchez-Corral P., Anton L.C., Alcolea J.M., Marques G., Sánchez A., and Vivanco F. Proteolytic activity of the different fragments of factor B on the third component of complement (C3). Involvement of the N-terminal domain of Bb in magnesium binding. Mol. Immunol. 27 (1990) 891-900
49. Sharma S., Jabeen T., Singh R.K., Bredhorst R., Vogel C.W., Betzel C., and Singh T.P. Structural studies on the cobra venom factor: isolation, purification, crystallization and preliminary crystallographic analysis. Acta Crystallogr. D Biol. Crystallogr. 57 (2001) 596-598
50. 2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 19 (2003) 391-402
51. Storoni L.C., McCoy A.J., and Read R.J. Likelihood-enhanced fast rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 432-438
52. Taniguchi-Sidle A., and Isenman D.E. Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at the N-terminus of C3 α'-chain. J. Immunol. 153 (1994) 5285-5302
53. Tomana M., Niemann M., Garner C., and Volanakis J.E. Carbohydrate composition of the second, third and fifth components and factors B and D of human complement. Mol. Immunol. 22 (1985) 107-111
54. Vogel C.W., and Müller-Eberhard H.J. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase. Proc. Natl. Acad. Sci. USA 78 (1981) 7707-7711
55. Vogel C.W., and Müller-Eberhard H.J. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J. Biol. Chem. 257 (1982) 8292-8299
56. Vogel C.W., and Müller-Eberhard H.J. Cobra venom factor: improved method for purification and biochemical characterization. J. Immunol. Methods 73 (1984) 203-220
57. Vogel C.W., Smith C.A., and Müller-Eberhard H.J. Cobra venom factor: structural homology with the third component of human complement. J. Immunol. 133 (1984) 3235-3241
58. Vogt W., Schmidt G., Von Buttlar B., and Dieminger L. A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology 34 (1978) 29-40
59. von Zabern I., Hinsch B., Przyklenk H., Schmidt G., and Vogt W. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology 157 (1980) 499-514
60. Whaley K., and Ruddy S. Modulation of the alternative complement pathways by β1H globulin. J. Exp. Med. 144 (1976) 1147-1163
61. Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M., Fairbrother W.J., McCallum S.A., Embuscado L., DeForge L., Hass P.E., and van Lookeren Campagne M. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444 (2006) 217-220
62. Xu Y., and Volanakis J.E. Contribution of the complement control protein modules of C2 in C4b binding assessed by analysis of C2/factor B chimeras. J. Immunol. 158 (1997) 5958-5965
63. Xu Y., Narayana S.V., and Volanakis J.E. Structural biology of the alternative pathway convertase. Immunol. Rev. 180 (2001) 123-135